Cargando…

Trends in treatment and survival of patients with nonresected, nonmetastatic pancreatic cancer: A population‐based study

BACKGROUND: Nonresected, nonmetastatic (NR‐M0) pancreatic cancer involves both locally advanced pancreatic cancer and patients who did not undergo resection due to poor health status or patient preference. This study investigates nationwide trends of characteristics, treatment, and survival of patie...

Descripción completa

Detalles Bibliográficos
Autores principales:	van der Geest, Lydia G. M., van Eijck, Casper H. J., Groot Koerkamp, Bas, Lemmens, Valery E. P. P., Busch, Olivier R., Vissers, Pauline A. J., Wilmink, Johanna W., Besselink, Marc G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6198237/ https://www.ncbi.nlm.nih.gov/pubmed/30188015 http://dx.doi.org/10.1002/cam4.1750

Ejemplares similares

Nationwide trends in chemotherapy use and survival of elderly patients with metastatic pancreatic cancer
por: van der Geest, Lydia G. M., et al.
Publicado: (2017)

The systemic immune‐inflammation index is associated with an increased risk of incident cancer—A population‐based cohort study
por: Fest, Jesse, et al.
Publicado: (2019)

Treatment Response and Conditional Survival in Advanced Pancreatic Cancer Patients Treated with FOLFIRINOX: A Multicenter Cohort Study
por: van der Sijde, Fleur, et al.
Publicado: (2022)

Conditional Survival After Resection for Pancreatic Cancer: A Population-Based Study and Prediction Model
por: Latenstein, Anouk E. J., et al.
Publicado: (2020)

The use of adjuvant chemotherapy for pancreatic cancer varies widely between hospitals: a nationwide population‐based analysis
por: Bakens, Maikel J., et al.
Publicado: (2016)

Circulating Biomarkers for Prediction of Objective Response to Chemotherapy in Pancreatic Cancer Patients
por: van der Sijde, Fleur, et al.
Publicado: (2019)

Real‐world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma
por: de Jong, Evelien J. M., et al.
Publicado: (2021)

Pressurized intraperitoneal aerosol chemotherapy procedure for nonresectable peritoneal carcinomatosis: First Indian study
por: Somashekhar, S. P., et al.
Publicado: (2019)

Current evidence of nutritional therapy in pancreatoduodenectomy: Systematic review of randomized controlled trials
por: Takagi, Kosei, et al.
Publicado: (2019)

Sex, Gender and Age Differences in Treatment Allocation and Survival of Patients With Metastatic Pancreatic Cancer: A Nationwide Study
por: Pijnappel, Esther N., et al.
Publicado: (2022)

Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer
por: Janssen, Quisette P., et al.
Publicado: (2020)

Organoids Derived from Neoadjuvant FOLFIRINOX Patients Recapitulate Therapy Resistance in Pancreatic Ductal Adenocarcinoma
por: Farshadi, Elham Aida, et al.
Publicado: (2021)

Meta‐analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer
por: Versteijne, E., et al.
Publicado: (2018)

Added Value of Radiotherapy Following Neoadjuvant FOLFIRINOX for Resectable and Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis
por: Janssen, Quisette P., et al.
Publicado: (2021)

Locally Advanced Pancreatic Cancer: Work-Up, Staging, and Local Intervention Strategies
por: van Veldhuisen, Eran, et al.
Publicado: (2019)

The value of serum amylase and drain fluid amylase to predict postoperative pancreatic fistula after pancreatoduodenectomy: a retrospective cohort study
por: van Dongen, Jelle C., et al.
Publicado: (2021)

Treatment and Survival of Elderly Patients with Stage I–II Pancreatic Cancer: A Report of the EURECCA Pancreas Consortium
por: Groen, Jesse V., et al.
Publicado: (2020)

Nationwide treatment and outcomes of perihilar cholangiocarcinoma
por: van Keulen, Anne‐Marleen, et al.
Publicado: (2021)

National Cancer Database report of nonmetastatic esophageal small cell carcinoma
por: Verma, Vivek, et al.
Publicado: (2018)

Cachexia, dietetic consultation, and survival in patients with pancreatic and periampullary cancer: A multicenter cohort study
por: Latenstein, Anouk E. J., et al.
Publicado: (2020)

FOLFIRINOX and radiotherapy for locally advanced pancreatic cancer: A cohort study
por: Suker, Mustafa, et al.
Publicado: (2018)

Prognostic analysis of postoperative clinically nonmetastatic renal cell carcinoma
por: Shao, Yanxiang, et al.
Publicado: (2019)

Utilization of short-course radiation therapy for patients with nonmetastatic rectal adenocarcinoma in the United States
por: Abdel-Rahman, Omar, et al.
Publicado: (2018)

Nationwide Impact of Centralization, Neoadjuvant Therapy, Minimally Invasive Surgery, and Standardized Pathology Reporting on R0 Resection and Overall Survival in Pancreatoduodenectomy for Pancreatic Cancer
por: Augustinus, Simone, et al.
Publicado: (2023)

Randomized clinical trial and meta-analysis of the impact of a fibrin sealant patch on pancreatic fistula after distal pancreatectomy: CPR trial
por: Mungroop, T H, et al.
Publicado: (2021)

The neutrophil-to-lymphocyte ratio is associated with mortality in the general population: The Rotterdam Study
por: Fest, Jesse, et al.
Publicado: (2018)

Time‐dependent and nonlinear effects of prognostic factors in nonmetastatic colorectal cancer
por: Chi, Sheng‐Qiang, et al.
Publicado: (2017)

The impact of squamous cell carcinoma histology on outcomes in nonmetastatic pancreatic cancer
por: Gruhl, Joshua D., et al.
Publicado: (2020)

Chyle Leak After Pancreatoduodenectomy: Clinical Impact and Risk Factors in a Nationwide Analysis
por: Augustinus, Simone, et al.
Publicado: (2023)

Nonmetastatic breast cancer patients subsequently developing second primary malignancy: A population‐based study
por: Bao, Shengnan, et al.
Publicado: (2021)

Serum cytokine levels are associated with tumor progression during FOLFIRINOX chemotherapy and overall survival in pancreatic cancer patients
por: van der Sijde, Fleur, et al.
Publicado: (2022)

Circulating TP53 mutations are associated with early tumor progression and poor survival in pancreatic cancer patients treated with FOLFIRINOX
por: van der Sijde, Fleur, et al.
Publicado: (2021)

Serum miR-373-3p and miR-194-5p Are Associated with Early Tumor Progression during FOLFIRINOX Treatment in Pancreatic Cancer Patients: A Prospective Multicenter Study
por: van der Sijde, Fleur, et al.
Publicado: (2021)

Significance of delayed primary excision in localized nonmetastatic adult head and neck rhabdomyosarcoma
por: Kobayashi, Kenya, et al.
Publicado: (2016)

Trends in Overall Survival and Treatment Patterns in Two Large Population-Based Cohorts of Patients with Breast and Colorectal Cancer
por: van Abbema, Doris, et al.
Publicado: (2019)

Role of Serum Lymphocyte-derived Biomarkers in Nonmetastatic Muscle-invasive Bladder Cancer Patients Treated with Trimodal Therapy
por: Kool, Ronald, et al.
Publicado: (2021)

Plasma and Urine Free Glycosaminoglycans as Monitoring Biomarkers in Nonmetastatic Renal Cell Carcinoma—A Prospective Cohort Study
por: Gatto, Francesco, et al.
Publicado: (2022)

Clinical significance of glycoprotein nonmetastatic B and its association with HER2 in breast cancer
por: Kanematsu, Masako, et al.
Publicado: (2015)

Patient and caregiver benefit‐risk preferences for nonmetastatic castration‐resistant prostate cancer treatment
por: Srinivas, Sandy, et al.
Publicado: (2020)

Factors associated with cognitive impairment during the first year of treatment for nonmetastatic breast cancer
por: Rodriguez, Nicole, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2ide7f09kshdbsk5oadhie1mdu